Clinical Trial Update: A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating an intravesical delivery system of erdafitinib in Japanese patients with bladder cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Erdafitinib (erdafitinib)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Status: ACTIVE_NOT_RECRUITING